2023-08-14 07:37:15 ET
- PDS Biotechnology press release ( NASDAQ: PDSB ): Q2 GAAP EPS of -$0.37 misses by $0.02 .
- Cash and cash equivalents as of June 30, 2023, totaled approximately $60.6 million. Based on the company’s cash resources, PDS Biotech believes this amount is sufficient to fund operations and research and development programs for 12 months following the filing of the Company’s June 2023 Quarterly Report on Form 10-Q which will be filed as of the date of this press release.
For further details see:
PDS Biotechnology GAAP EPS of -$0.37 misses by $0.02